Prescriber & Patient Portal
Login | Registration

Weight Loss

Whether you’re looking for prescription medications, supplements, or customized formulations, we have options to support your weight loss journey. Our comprehensive approach includes personalized consultations and ongoing support to help you stay on track.

Ready to take the first step towards a healthier you? Download our Formulary here to explore our range of weight loss solutions and start your journey today!

Welcome to Mycelium Pharmacy’s Weight Loss Solutions page! We understand that weight loss can be a challenging journey, which is why we offer personalized solutions tailored to your needs. Our expert team is dedicated to helping you achieve your weight loss goals in a safe and effective manner.

The Science Behind Sublingual Semaglutide

The sublingual formulation uses SubMagna delivery system technology which is a self-emulsifying, anhydrous vehicle that enhances permeation of Semaglutide.

Upon administration of the formulation sublingually, the drug forms an emulsion with saliva which greatly enhances its solubility and absorption of the active ingredient (Semaglutide).

SubMagna™ Delivery System

The SubMagna™ delivery system represents a breakthrough in drug delivery technology, facilitating the efficient absorption of semaglutide through the sublingual mucosa.

This innovative system utilizes magnetic nanoparticles to enhance drug permeation and bioavailability, ensuring consistent plasma levels and optimized therapeutic effects.

The ease of use and non-invasive nature of the SubMagna™ device make it an attractive option for patients seeking convenient and effective weight loss solutions.

Mechanism Of Action

Sublingual semaglutide exerts its effects by mimicking the action of endogenous GLP 1, stimulating insulin secretion, suppressing glucagon release, and promoting satiety. Additionally, it slows gastric emptying, leading to reduced food intake and weight loss.

The sublingual route of administration bypasses the gastrointestinal tract, ensuring rapid absorption and bioavailability, thus enhancing the therapeutic effects of semaglutide.


Clinical trials evaluating sublingual semaglutide have demonstrated significant weight loss outcomes comparable to injectable formulations.

The STEP program (Semaglutide Treatment Effect in People with Obesity) showcased impressive results, with participants achieving substantial weight reduction and improvements in cardiometabolic parameters.

The convenience of sublingual administration and the absence of injection-related adverse events may further enhance patient adherence to long-term treatment regimens.

Safety Profile

Sublingual semaglutide is generally well-tolerated, with the most common side effects being gastrointestinal disturbances such as nausea and diarrhea.

The sublingual route of administration may result in gastrointestinal adverse events compared to injectable formulations.

However, caution is warranted in individuals with a history of pancreatitis or thyroid carcinoma, and close monitoring for potential cardiovascular risks is essential, particularly in high-risk populations. 

Additional Tips

The GLP 1 agonist medications for weight loss as sublingual semaglutide are not medications that you want to start using on your own.

If you are considering these medications, you must consult your healthcare provider to learn more about them and learn more about other options for diabetes and obesity treatment.

They also have some side effects which makes it more important to work closely beside your healthcare provider to ensure your safety. 

Future Directions

The development of sublingual semaglutide and the SubMagna delivery system begins a new era in weight management, offering a promising alternative to traditional approaches.

Future research purposes may focus on optimizing dosing regimens, exploring combination therapies, and elucidating the long-term safety and efficacy of sublingual semaglutide.

Additionally, efforts to enhance patient education and access to these innovative therapies are crucial for addressing the global burden of obesity and improving public health outcomes.


Sublingual semaglutide, coupled with the SubMagna delivery system, represents a game-changer advancement in the field of weight management.

With its potent efficacy, favorable safety profile, and convenient administration, this novel therapeutic approach holds great promise for addressing the rapidly growing obesity issue and improving the lives of millions worldwide.

Continued research and innovation are essential to unlock the full potential of sublingual semaglutide and revolutionize the landscape of weight loss treatment.